Woodline Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Woodline Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-123,502	Closed	-$18M	–	980
2022 Q2	$18M	Buy	+123,502	New	+$15.8M	0.28%	112
2021 Q4	–	Sell	-40,515	Closed	-$5.63M	–	877
2021 Q3	$5.63M	Sell	40,515 -81,893	-67%	-$10.2M	0.09%	240
2021 Q2	$11.9M	Sell	122,408 -65,848	-35%	-$5.34M	0.22%	117
2021 Q1	$12.9M	Buy	+188,256	New	+$15.2M	0.29%	95
2020 Q3	–	Sell	-61,221	Closed	-$4.48M	–	230
2020 Q2	$4.48M	Buy	+61,221	New	+$3.26M	0.18%	118

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Woodline Partners's BHVN Position: Q3 2022 in Review

Woodline Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 123,502 shares — an estimated $18M sold.

Woodline Partners first reported a position in BHVN in Q2 2020 and held it in 5 quarters. The position peaked at $18M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Woodline Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Woodline Partners sold 123,502 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $18M.
Woodline Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 5 quarters.
Woodline Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $18M in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.